• Fri news: Pfizer’s $1B Chinese commitment. RFK Jr. and pharma. Eisai dials back Leqembi forecast. US diabetes burden increase. JNJ gets Varipulse approval. See more on our front page

Amylin Sues Lilly

Quote








Why is it unreasonable for Lilly to have separate sales forces promoting the DPPIV and Byetta?

Every Lilly rep that has sold Byetta recognizes that it puts them in an awkward position to now sing praises of the efficacy of the DPPIV class after years of pointing out their lack of sustained efficacy.

Lilly's actions are further validation of their upper managements complete lack of understanding their own market. The Eli Lilly of today looks nothing like the Lilly that launched Prozac. Lilly's management is enamored with their legacy of greatness while doing nothing to actually sustain greatness. Novo and Sanofi own the insulin market. Effient? not exactly a blockbuster Forteo launched with a black cloud. The marketing of Zyprexa certainly marred and costed Lilly. When Actos finally gained some traction-Lilly was out of the picture.

So Lilly's greatness has done what for Byetta? Managed care-nope that is Amylin's.

If you asked ICOS or Takeda if they could do it all over, I bet they would say yes. The decision to partner with Lilly was a poor one. I would guess Amylin is saying the same thing. Poor BI, they will figure it out soon enough.

So good for Lilly. The medical professionals who treat diabetes already view Lilly's insulin portfolio as second rate to Novo. A third in class DPPIV will not excite these folks and by the time their third in class basal sees the market, Lilly's reputation as a second rate pharmaceutical the company will be so firmly planted in the medical community, Eli will be rolling over in his grave.

Astounding that Lilly's BOD doesn't see through the management's thin veil of competency.
Maybe they will when the Wall Street Journal starts referring to Lilly as a "former" industry leader.

Good luck Lilly with your 3rd/last in class products. Last and Lilly has certain ring to it. It is too bad. Too bad for their employees, their shareholders and their business partners.
 








Anonymous said:
Why is it unreasonable for Lilly to have separate sales forces promoting the DPPIV and Byetta?

Every Lilly rep that has sold Byetta recognizes that it puts them in an awkward position to now sing praises of the efficacy of the DPPIV class after years of pointing out their lack of sustained efficacy.

Lilly's actions are further validation of their upper managements complete lack of understanding their own market. The Eli Lilly of today looks nothing like the Lilly that launched Prozac. Lilly's management is enamored with their legacy of greatness while doing nothing to actually sustain greatness. Novo and Sanofi own the insulin market. Effient? not exactly a blockbuster Forteo launched with a black cloud. The marketing of Zyprexa certainly marred and costed Lilly. When Actos finally gained some traction-Lilly was out of the picture.

So Lilly's greatness has done what for Byetta? Managed care-nope that is Amylin's.

If you asked ICOS or Takeda if they could do it all over, I bet they would say yes. The decision to partner with Lilly was a poor one. I would guess Amylin is saying the same thing. Poor BI, they will figure it out soon enough.

So good for Lilly. The medical professionals who treat diabetes already view Lilly's insulin portfolio as second rate to Novo. A third in class DPPIV will not excite these folks and by the time their third in class basal sees the market, Lilly's reputation as a second rate pharmaceutical the company will be so firmly planted in the medical community, Eli will be rolling over in his grave.

Astounding that Lilly's BOD doesn't see through the management's thin veil of competency.
Maybe they will when the Wall Street Journal starts referring to Lilly as a "former" industry leader.

Good luck Lilly with your 3rd/last in class products. Last and Lilly has certain ring to it. It is too bad. Too bad for their employees, their shareholders and their business partners.
Click to expand...

I have rebuild Lilly into my own glorious image. It is a sight to behold. Bow before the belly of King John as you are all unworthy of employment here. Your contributions are but a pittance when compared to my legacy of innovation that will shine forever. King-O-FIPNET
 




Anonymous said:
I am JohnCL. I come to you from the pure, pristine Appalachian pastures by way of Harvard. I come bearing ARTWORKS, Veritas et Integrité. My Innovation and multiple chin-folds give you a world of pleasure and bliss. I have never laid off a valued employee ever. I am of Honor and Integrity. Always. I am for You.
Click to expand...

Remember that from PORK you came, and to PORK you shall return.
 




Hey this lawsuit may or may not be successful. However, it paves the way for other future FIPNET related lawsuits. After all, with more than one partner for any given indication, conflicts are bound to arise, and allegations of conflicts even more plentiful.

No matter how much Lilly spends on it's public image, the underlying reality is that real innovation has not been conducted within Lilly for at least a decade. All "advances" have been the product of research and development by other companies, for example ICOS. As a financial heavyweight with abundant cash flow, you can get away with this, once or twice. However, do what we did to the ICOS staff and you make enemies, and also garner a pretty undesirable reputation. Likewise with Amylin. Maybe soon, with BI, too.

Why was Novartis so swift and graceful in capturing Lilly's insulin franchise? Maybe the same reason that they had ads on PBS radio for years describing in a brief articulate sentence what their mission was: TO HELP THE PATIENT. Now there is a very successful case of winning hearts and minds, and they did it in a forum where mostly the most intelligent listen during the morning and evening commute. In a word, brilliant.
 




Anonymous said:
Why was Novartis so swift and graceful in capturing Lilly's insulin franchise? Maybe the same reason that they had ads on PBS radio for years describing in a brief articulate sentence what their mission was: TO HELP THE PATIENT. Now there is a very successful case of winning hearts and minds, and they did it in a forum where mostly the most intelligent listen during the morning and evening commute. In a word, brilliant.
Click to expand...

Contrast Novartis' approach with lLy's: Local PBS station has LILLY LIFESCIENCE MINUTE, with the failed, exMayor baART staring into a camera, mouthing idiocy (or rather INDIOCY) in front of a fake, grade school cgi image of a "Lost in Space" control panel. The message: WHO IS THE CLOWNTARD? CHANGE THE CHANNEL, NOW!
 




Amylin's CEO delivers a knockout punch to Lilly today. At the shareholder meeting, he announced the $165M from Lilly and lawsuit against Lilly. Who is a better strategic player? Why Lilly gave the money if they knew the were being sued?
 




Well with the action taken by Amylin and the courts, Lilly just needs to stop selling Byetta for a few months or so and watch Amylin wither like a flower sprayed with round-up.
 




















Top Bottom
Back
Quote